Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder

Aaberg, 2018, Short-term seizure outcomes in childhood epilepsy, Pediatrics, 141, 10.1542/peds.2017-4016 Amada, 2013, Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression, PeerJ, 1, 10.7717/peerj.214 Amir, 1999, Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2, Nature Genetics, 23, 185, 10.1038/13810 Anavi-Goffer, 2012, Modulation of L-alpha-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids, The Journal of Biological Chemistry, 287, 91, 10.1074/jbc.M111.296020 Araque, 2017, Synaptic functions of endocannabinoid signaling in health and disease, Neuropharmacology, 124, 13, 10.1016/j.neuropharm.2017.06.017 Bahi-Buisson, 2008, Parental view of epilepsy in Rett Syndrome, Brain & Development, 30, 126, 10.1016/j.braindev.2007.07.002 Bialer, 2017, Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII), Epilepsia., 58, 181, 10.1111/epi.13634 Bisogno, 2001, Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, British Journal of Pharmacology, 134, 845, 10.1038/sj.bjp.0704327 Byiers, 2014, Seizures and pain uncertainty associated with parenting stress and Rett syndrome, Journal of Child Neurology, 29, 526, 10.1177/0883073812470736 Chanda, 2019, The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target, Prostaglandins, Leukotrienes, and Essential Fatty Acids, 140, 51, 10.1016/j.plefa.2018.11.016 Chen, 2007, Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures, The Journal of Neuroscience, 27, 46, 10.1523/JNEUROSCI.3966-06.2007 Chen, 2003, Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures, Neuron, 39, 599, 10.1016/S0896-6273(03)00499-9 Cooray, 2020, Current aspects of the Endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s diseases: A review, Molecular Neurobiology, 57, 4878, 10.1007/s12035-020-02054-6 Cristino, 2020, Cannabinoids and the expanded endocannabinoid system in neurological disorders, Nature Reviews. Neurology, 16, 9, 10.1038/s41582-019-0284-z De Petrocellis, 2011, Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes, British Journal of Pharmacology, 163, 1479, 10.1111/j.1476-5381.2010.01166.x DeFilippis, 2016, Treatment of autism spectrum disorder in children and adolescents, Psychopharmacology Bulletin, 46, 18 Devinsky, 2018, Epilepsy, Nature Reviews. Disease Primers, 4, 10.1038/nrdp.2018.24 Falenski, 2009, Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus, Brain Research, 1262, 64, 10.1016/j.brainres.2009.01.036 Fisher, 2014, ILAE official report: A practical clinical definition of epilepsy, Epilepsia, 55, 475, 10.1111/epi.12550 Fusar-Poli, 2020, Cannabinoids for people with ASD: A systematic review of published and ongoing studies, Brain Sciences, 10, 572, 10.3390/brainsci10090572 Good, 2021, MeCP2: The genetic driver of Rett syndrome epigenetics, Frontiers in Genetics, 12, 620859, 10.3389/fgene.2021.620859 Gould, 2014, Enhanced novelty-induced corticosterone spike and upregulated serotonin 5-HT1A and cannabinoid CB1receptors in adolescent BTBR mice, Psychoneuroendocrinology, 39, 158, 10.1016/j.psyneuen.2013.09.003 Greco, 2018, Investigational small molecules in phase 2 clinical trials for the treatment of epilepsy, Expert Opinion on Investigational Drugs, 27, 971, 10.1080/13543784.2018.1543398 Guang, 2018, Synaptopathology involved in autism Spectrum disorder, Frontiers in Cellular Neuroscience, 12, 470, 10.3389/fncel.2018.00470 Han, 2012, Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD, Cell, 148, 1039, 10.1016/j.cell.2012.01.037 Hill, 2012, Cannabidivarin is anticonvulsant in mouse and rat, British Journal of Pharmacology, 167, 1629, 10.1111/j.1476-5381.2012.02207.x Hill, 2013, Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism, British Journal of Pharmacology, 170, 679, 10.1111/bph.12321 Huizenga, 2019, Preclinical safety and efficacy of cannabidivarin for early life seizures, Neuropharmacology, 148, 189, 10.1016/j.neuropharm.2019.01.002 Iannotti, 2014, Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: Potential for the treatment of neuronal hyperexcitability, ACS Chemical Neuroscience, 5, 1131, 10.1021/cn5000524 Iannotti, 2019, Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice, British Journal of Pharmacology, 176, 1568, 10.1111/bph.14460 Jiang, 2013, Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19, drug metab, Pharmacokinetics, 28, 332 Jung, 2012, Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome, Nature Communications, 3, 1080, 10.1038/ncomms2045 Kano, 2009, Endocannabinoid-mediated control of synaptic transmission, Physiological Reviews, 89, 309, 10.1152/physrev.00019.2008 Kerr, 2013, Alterations in the endocannabinoid system in the rat valproic acid model of autism, Behavioural Brain Research, 249, 124, 10.1016/j.bbr.2013.04.043 Laun, 2019, GPR3, GPR6, and GPR12 as novel molecular targets: Their biological functions and interaction with cannabidiol, Acta Pharmacologica Sinica, 40, 300, 10.1038/s41401-018-0031-9 Ligresti, 2004, Further evidence for the existence of a specific process for the membrane transport of anandamide, The Biochemical Journal, 380, 265, 10.1042/bj20031812 Liu, 2020, Excitation and inhibition balance underlying epileptiform activity, IEEE Transactions on Biomedical Engineering, 67, 2473, 10.1109/TBME.2019.2963430 Lord, 2018, Autism spectrum disorder, Lancet, 392, 508, 10.1016/S0140-6736(18)31129-2 Löscher, 2020, Drug-resistant epilepsy, Pharmacological Reviews, 72, 606, 10.1124/pr.120.019539 Ludanyi, 2008, Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus, The Journal of Neuroscience, 28, 2976, 10.1523/JNEUROSCI.4465-07.2008 Mannucci, 2017, Neurological aspects of medical use of cannabidiol, CNS & Neurological Disorders Drug Targets, 16, 541, 10.2174/1871527316666170413114210 Marco, 2012, The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives, Journal of Psychopharmacology, 26, 150, 10.1177/0269881111408459 Marsicano, 2009, Roles of the endocannabinoid system in learning and memory, Current Topics in Behavioral Neurosciences, 1, 201, 10.1007/978-3-540-88955-7_8 Martínez, 2020, Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: Useful nutraceuticals?, International Journal of Molecular Sciences, 21, 3067, 10.3390/ijms21093067 Mazur, 2009, Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids, Drug Metab Dispos, 37, 1496, 10.1124/dmd.109.026898 Melancia, 2018, Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling, British Journal of Pharmacology, 175, 3699, 10.1111/bph.14435 Meng, 2014, Astrocytic expression of cannabinoid type 1 receptor in rat and human sclerotic hippocampi, International Journal of Clinical and Experimental Pathology, 7, 2825 Monory, 2015, Cannabinoid CB1 receptor calibrates excitatory synaptic balance in the mouse hippocampus, The Journal of Neuroscience, 35, 3842, 10.1523/JNEUROSCI.3167-14.2015 Morano, 2016, Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin, Epilepsia Open, 1, 145, 10.1002/epi4.12015 Morano, 2020, Cannabinoids in the treatment of epilepsy: Current status and future prospects, Neuropsychiatric Disease and Treatment, 16, 381, 10.2147/NDT.S203782 Mottron, 2020, Autism spectrum heterogeneity: Fact or artifact?, Molecular Psychiatry, 25, 3178, 10.1038/s41380-020-0748-y Muller, 2019, Cannabinoid ligands targeting TRP channels, Frontiers in Molecular Neuroscience, 11, 487, 10.3389/fnmol.2018.00487 Nakano, 2019, Development of a novel nano­emulsion formulation to improve intestinal absorption of cannabidiol, Medical Cannabis and Cannabinoids, 2, 35, 10.1159/000497361 Navarro, 2020, Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors, Pharmacological Research, 159, 104940, 10.1016/j.phrs.2020.104940 Neul, 2010, Rett syndrome: Revised diagnostic criteria and nomenclature, Annals of Neurology, 68, 944, 10.1002/ana.22124 Ornoy, 2019, Prevention or amelioration of autism-like symptoms in animal models: Will it bring us closer to treating human ASD?, International Journal of Molecular Sciences, 20, 10.3390/ijms20051074 Pagano, 2019, The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients, Pharmacological Research, 149, 104464, 10.1016/j.phrs.2019.104464 Palma, 2007, GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) “phasic” receptors, Proceedings of the National Academy of Sciences of the United States of America, 104, 20944, 10.1073/pnas.0710522105 Pamplona, 2018, Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: Observational data meta-analysis, Frontiers in Neurology, 9, 759, 10.3389/fneur.2018.00759 Pennell, 2020, Unravelling the heterogeneity of epilepsy for optimal individualised treatment: Advances in 2019, Lancet Neurology, 19, 8, 10.1016/S1474-4422(19)30430-2 Perucca, 2017, Cannabinoids in the treatment of epilepsy: Hard evidence at last?, Journal of Epilepsy Research, 7, 61, 10.14581/jer.17012 Pretzsch, 2019, Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): A single dose trial during magnetic resonance spectroscopy, Translational Psychiatry, 9, 313, 10.1038/s41398-019-0654-8 Ragozzino, 2005, Rundown of GABA type A receptors is a dysfunction associated with human drug-resistant mesial temporal lobe epilepsy, Proceedings of the National Academy of Sciences of the United States of America, 102, 15219, 10.1073/pnas.0507339102 Roullet, 2013, In utero exposure to valproic acid and autism-a current review of clinical and animal studies, Neurotoxicology and Teratology, 36, 47, 10.1016/j.ntt.2013.01.004 Russo, 2019, Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells, Archives of Toxicology, 93, 179, 10.1007/s00204-018-2322-9 Sadanandan, 2020, Cannabinoid type 2 receptors inhibit GABAA receptor-mediated currents in cerebellar Purkinje cells of juvenile mice, PLoS One, 15, 10.1371/journal.pone.0233020 Santosh, 2016, Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents, BJPsych Advances, 22, 151, 10.1192/apt.bp.115.014597 Schneider, 2005, Behavioral alterations in rats prenatally exposed to valproic acid: Animal model of autism, Neuropsychopharmacology, 30, 80, 10.1038/sj.npp.1300518 Shrader, 2020, Involvement of dopamine receptor in the actions of non-psychoactive phytocannabinoids, Biochemical and Biophysical Research Communications, 533, 1366, 10.1016/j.bbrc.2020.10.021 Smith, 2017, Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans, PLoS One, 12, 10.1371/journal.pone.0187926 Sohal, 2019, Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders, Molecular Psychiatry, 24, 1248, 10.1038/s41380-019-0426-0 Sugaya, 2018, Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling, Cellular and Molecular Life Sciences, 75, 2793, 10.1007/s00018-018-2834-8 Thornton, 2020, Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish, Epilepsy & Behavior, 110, 107152, 10.1016/j.yebeh.2020.107152 Trezza, 2012, Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats, The Journal of Neuroscience, 32, 14899, 10.1523/JNEUROSCI.0114-12.2012 Vázquez, 2021, Clinical pharmacokinetics of cannabinoids and potential drug-drug interactions, Advances in Experimental Medicine and Biology, 1297, 27, 10.1007/978-3-030-61663-2_3 Vigli, 2018, Chronic treatment with the phytocannabinoid cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome, Neuropharmacology, 140, 121, 10.1016/j.neuropharm.2018.07.029 Vollner, 1969, Cannabidivarin, a new hashish constituent, Tetrahedron Letters, 145, 10.1016/S0040-4039(01)87494-3 Wallace, 2003, The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy, Journal of Pharmacology and Experimental Therapeutics, 307, 129, 10.1124/jpet.103.051920 Wei, 2016, Enhancement of anandamide-mediated endocannabinoid signalingcorrects autism-related social impairment, Cannabis and Cannabinoid Research, 1, 81, 10.1089/can.2015.0008 WHO, Global Epilepsy Report, 2019, Epilepsy: a public health imperative Wu, 2020, Targeting the inhibition of fatty acid amide hydrolase ameliorate the endocannabinoidmediatedsynaptic dysfunction in a valproic acid induced rat model of autism, Neuropharmacology, 162, 10.1016/j.neuropharm.2019.107736 Yamaori, 2011, Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety, Life Sciences, 88, 730, 10.1016/j.lfs.2011.02.017 Yamaori, 2011, Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6, Drug Metabolism and Disposition, 39, 2049, 10.1124/dmd.111.041384 Yamaori, 2013, Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: Role of pentylresorcinol moiety, Biological & Pharmaceutical Bulletin, 36, 1197, 10.1248/bpb.b13-00183 Yamaori, 2014, Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol, Chemico-Biological Interactions, 215, 62, 10.1016/j.cbi.2014.03.007 Zagzoog, 2020, In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa, Scientific Reports, 10, 204.05, 10.1038/s41598-020-77175-y Zamberletti, 2019, Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice, Journal of Psychopharmacology, 33, 894, 10.1177/0269881119844184 Zamberletti, 2019, Cannabidivarin treatment ameliorates autism-like behaviors and restores hippocampal endocannabinoid system and glia alterations induced by prenatal valproic acid exposure in rats, Frontiers in Cellular Neuroscience, 13, 367, 10.3389/fncel.2019.00367 Zanger, 2013, Cytochrome P450 enzymes in drug metabolism: Reg- ulation of gene expression, enzyme activities, and impact of genetic variation, Pharmacology & Therapeutics, 138, 103, 10.1016/j.pharmthera.2012.12.007 Zendulka, 2016, Cannabinoids and cytochrome P450 interactions, Current Drug Metabolism, 17, 206, 10.2174/1389200217666151210142051 Zou, 2021, Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder, Open Biology, 11, 200306, 10.1098/rsob.200306